U.S. Rheumatoid Arthritis/Autoimmune Market

U.S. Rheumatoid Arthritis/Autoimmune Market 

• Uniform massive 5-7 fold U.S. price increases in the decade-plus since Medicare Part D began
  • from about $15,000 patient/year before Part D to the $75,000 patient/year range now
• Despite rising competition from numerous similar new drugs reaching the U.S market
  • U.S. market still dominated by AbbVie's Humira and Amgen's Enbrel
  • AbbVie's Humira is the world's top-selling drug, with 70% of its 2018 sales ($13.7 billion) in the U.S.
    • U.S. sales driven by far higher U.S. vs. international prices
  • Link to Whistlelblower table showing uniform and severe Humira and Enbrel U.S. price inflation over the past decade-plus

Amgen’s Enbrel (on U.S. market since 1997)

• 2005 Reported U.S. Sales: $2.47 billion
• 2017 Reported U.S. Sales: $5.2 billion
• U.S. Clinical Use/Prescriptions DOWN -25% since 2005
• 2017 U.S. Sales WITHOUT Price Increases: $1.9 billion
• 2005 U.S. “List”/“Sticker”: $15,000/patient/year
• 2018 U.S. “List”/“Sticker”: $75,000/patient/year
• Cumulative harm since start of Part D: $19.1+ billion
  • Link to Enbrel’s Whistleblower cumulative harm chart 

Abbvie’s Humira (on U.S. market since 2003)

• 2005 Reported U.S. Sales: $560 million
• 2017 Reported U.S. Sales: $12.4 billion
• 2017 U.S. Sales WITHOUT Price Increases: $3.8 billion
• 2005 U.S. “List”/“Sticker”: $15,000/patient/year
• 2018 U.S. “List”/“Sticker”: $75,000/patient/year
• Cumulative harm since start of Part D: $32.3+ billion
  • Link to Humira’s Whistleblower cumulative harm chart